CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Naproxen Sodium (Aleve) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00007189
NCT00007189Phase 3Completed
CompareCT.gov

Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

Seattle Institute for Biomedical and Clinical Research·interventional·Posted Dec 14, 2000·Updated Oct 19, 2016

In Brief

A Phase 3 clinical trial evaluating Naproxen Sodium (Aleve) and Celecoxib (Celebrex) for Alzheimer Disease. Completed, across 6 sites.

Detailed Summary

The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), VA Puget Sound Health Care System, University of Washington, Johns Hopkins University

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 14, 2000
Enrollment StartJan 1, 2001
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 25.6 years ago

Interventions

Naproxen Sodium (Aleve)drug

Celecoxib (Celebrex)drug